Analysts Set Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Target Price at $9.12

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.12.

A number of research firms have recently weighed in on AUTL. Wells Fargo & Company dropped their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, July 21st. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Saturday, September 27th. Finally, William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $26,000. Marex Group plc bought a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $28,000. R Squared Ltd bought a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $50,000. Delaney Dennis R bought a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $55,000. Finally, Forefront Wealth Management Inc. bought a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $61,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Down 4.5%

NASDAQ AUTL opened at $1.49 on Friday. The company has a 50-day simple moving average of $1.70 and a two-hundred day simple moving average of $1.78. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $5.00. The firm has a market cap of $396.55 million, a price-to-earnings ratio of -1.77 and a beta of 1.84.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $12.92 million. Equities analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.